Skip to main content

Table 3 Clinical and biochemical characteristics in the normotensive controls and HTN patient subgroups according to the PAM rs13175330 genotype

From: The peptidylglycine-α-amidating monooxygenase (PAM) gene rs13175330 A>G polymorphism is associated with hypertension in a Korean population

PAM rs13175330

Normotensive controls (n = 1610)

HTN group (n = 543)

HTN w/o therapy (n = 377)

HTN w/ therapy (n = 166)

AA (n = 1377)

G allele (n = 233)

AA (n = 305)

G allele (n = 72)

AA (n = 129)

G allele (n = 37)

Systolic BP (mmHg)

116.2

± 0.31

117.7

± 0.74

144.6

± 0.68

147.9

± 1.46*

123.2

± 0.90

123.4

± 1.70

Diastolic BP (mmHg)

72.6

± 0.23

73.3

± 0.58

91.4

± 0.45

93.8

± 1.11*

75.7

± 0.63

83.3

± 1.67***

Triglyceride (mg/dL)a

119.4

± 2.02

121.1

± 4.29

148.2

± 5.10

163.9

± 12.7

141.3

± 6.79

148.4

± 9.93

Total-cholesterol (mg/dL)a

198.0

± 0.96

198.6

± 2.53

201.7

± 2.06

194.1

± 4.43

193.8

± 3.01

194.5

± 5.97

HDL-cholesterol (mg/dL)a

54.0

± 0.37

53.5

± 0.84

50.3

± 0.73

50.4

± 1.45

50.7

± 1.20

49.7

± 1.98

LDL-cholesterol (mg/dL)a

121.1

± 0.88

121.1

± 2.20

122.7

± 1.99

112.0

± 3.71*

115.5

± 2.66

115.1

± 4.63

Glucose (mg/dL)a

95.5

± 0.55

96.5

± 1.47

103.7

± 1.49

104.8

± 3.76

105.7

± 2.08

97.5

± 2.56*

Insulin (μIU/dL)a

9.07

± 0.13

9.26

± 0.28

9.60

± 0.33

12.1

± 0.99**

9.56

± 0.38

10.4

± 0.79

HOMA-IRa

2.14

± 0.04

2.21

± 0.08

2.50

± 0.11

3.29

± 0.41**

2.45

± 0.11

2.40

± 0.17

LDL particle size (nm)a

23.9

± 0.04

24.0

± 0.06

24.0

± 0.07

23.5

± 0.12**

24.0

± 0.09

23.9

± 0.17

Oxidized LDL (U/L)a

45.9

± 0.56

47.4

± 1.53

49.8

± 1.27

55.0

± 2.70*

43.7

± 2.09

43.7

± 2.85

  1. Mean ± SE
  2. HTN hypertension, HTN w/o therapy HTN group treated without antihypertensive therapy, HTN w/ therapy HTN group treated with antihypertensive therapy, BP blood pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, PAM peptidylglycine-α-amidating monooxygenase
  3. p < 0.1, * p < 0.05, ** p < 0.01, and *** p < 0.001 derived from an independent t test within the normotensive controls and each HTN subgroup
  4. aTested following logarithmic transformation